M&A

Five things for pharma marketers to know: Monday, January 26

Five things for pharma marketers to know: Monday, January 26

By

Actavis acquires Auden Mckenzie for $459 million; Sanofi/Regeneron's PCSK9 inhibitor could be first to market; Gilead strikes a deal for Harvoni and Sovaldi with four German health insurers.

Actavis CEO touts his acquisition strategy

Brent Saunders, the mind behind the $66 billion acquisition of Allergan, which elevated Actavis to the tenth-largest drugmaker in the world, tells Forbes that growth through acquisition is not simply a short-term tactic but part of a long-term strategy.

Five things for pharma marketers to know: Friday, January 16

Five things for pharma marketers to know: Friday, January 16

By By

CMS head Marilyn Tavenner has resigned; Depomed acquires Nucynta pain pill from J&J; Merck's innovation lead leaves for insurer.

Five things for pharma marketers to know: Tuesday, January 13

Five things for pharma marketers to know: Tuesday, January 13

By By

Prime Therapeutics gives Gilead's Harvoni and AbbVie's Viekira Pak preferred formulary status; Novartis and Qualcomm team up for new investment firm; UK cost watchdog axes cancer drug coverage.

Five things for pharma marketers to know Wednesday, January 7

Five things for pharma marketers to know Wednesday, January 7

By

India's Patent Office sets aside Humira patent; Gilead acquires fatty liver disease agent; Bloomberg report says M&A activity likely to persist in 2015.

Sanofi looks to join M&A trend

Interim CEO Serge Weinberg tells a German paper that the company is prepared to buy assets that meet its goal of providing stable, steady growth.

Five things for pharma marketers to know: Monday, December 8

Five things for pharma marketers to know: Monday, December 8

By

Merck buys up Cubist in an $8.4B deal, a jury sides with AstraZeneca in a generic Nexium lawsuit and the NYT finds a correlation between Genentech payments and Lucentis prescriptions.

Five things for pharma marketers to know: Monday, November 17

Five things for pharma marketers to know: Monday, November 17

By

Actavis and Allergan have a $66-billion-dollar deal, Merck's Vytorin hits its endpoint, and Pfizer puts up $850 million for an experimental cancer drug.

Valeant wins over docs with trips, fees

Valeant's war for Allergan also includes a soft touch when it comes to doctors: the WSJ reports that the company is winning over professionals with trips and consulting offers.

Five things for pharma marketers to know: Thursday, November 13

Five things for pharma marketers to know: Thursday, November 13

By

Actavis and Allergan are close to a deal in the $60-billionish range; AstraZeneca is working on a Brilinta antidote; scientists find what amounts to a naturally occurring version of Merck's Zetia.

Actavis, Sanofi reportedly spar for Omega

Bloomberg reports that the race to merge with Omega also includes privately-held Boehringer Ingelheim and Perrigo.

Five things for pharma marketers to know: Friday,  October 17

Five things for pharma marketers to know: Friday, October 17

By

Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.

AbbVie-free Shire could open new opportunities

AbbVie-free Shire could open new opportunities

By

AbbVie's board is encouraging shareholders to kill the Shire acquisition, and analysts say a breakup would still leave Shire in a strong position.

Becton Dickinson buys CareFusion

An analyst says the $12.2B deal creates a one-stop shopping experience for hospitals.

Five things for pharma marketers to know: Friday, October 3

Five things for pharma marketers to know: Friday, October 3

By

Salix-Cosmo tax-inversion deal quashed, chronic heart failure market set to expand, rising generic drug prices get lawmakers' attention, NICE gives leukemia drug a thumbs-down, FDA has a good rep

Pharma M&A activity rebounds in 2013: report

Pharma M&A activity rebounds in 2013: report

By

Driven by a number of high-profile buys in 2013, pharma saw a return to investment through acquisition after a 2012 dip.

Covidien buys firm armed with missile tech

Covidien is buying ingestible-camera company Given Imaging.

Actavis may buy Warner Chilcott

By

Already the world's third-largest generics maker, Actavis stands to gain if it can seal the deal

Pharmas to biotechs: let's make a deal

Pharmas to biotechs: let's make a deal

By

Having finally accepted that external R&D is the future, big pharmas are snapping up earlier-stage biotechs and biologics, but they're not betting the farm on them, thanks to pre-nup-like earnout deals.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.

Email Newsletters